A
Altura Medical
Emerging medical device company developing a next generation endograft technology to treat abdominal aortic aneurysms
About Altura Medical
Founded in 2008 and based in Menlo Park, California, Altura Medical operated in the medical device sector with a specific focus on treating abdominal aortic aneurysms (AAAs). The company, formerly known as Altura Interventional Inc., developed an endovascular stent graft system designed to offer a less invasive solution for a condition that can be life-threatening if left untreated.
The core of Altura Medical's business was its proprietary stent graft technology. This system featured a distinct bilateral D-stent design, which set it apart by eliminating the need for contralateral limb cannulation, a common step in similar procedures. This simplified the surgical process, potentially reducing procedure times. The device was delivered via an ultra-low-profile 14F system, designed to minimize trauma to the blood vessels during insertion. A key benefit of the system was the ability to reposition the dual aortic endografts during deployment, allowing surgeons to achieve precise placement and maximize the sealing zone just below the renal arteries. Comprised of a braided nitinol endoskeleton and woven polyester graft material, the components were engineered for flexibility and durable sealing.
The company's primary clients were hospitals and vascular surgeons trained in endovascular aneurysm repair (EVAR). In 2015, Altura Medical achieved a significant milestone by obtaining a CE Mark for its endograft system, permitting its sale and use within the European Union. Following this regulatory achievement, Altura Medical was acquired by Lombard Medical in July 2015. The deal was valued at a potential total of over $50 million, consisting of an initial $23 million in stock and assumed liabilities, with up to an additional $27.5 million contingent on regulatory and commercial milestones. At the time of the acquisition, Lombard planned to launch the device in Europe in early 2016 and pursue an Investigational Device Exemption (IDE) from the U.S. FDA to begin clinical trials in the United States.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2015 | $51M | $51M | Undisclosed | — |
| EARLY VC✓Equity / VC | Apr 2013 | $6M | $24M | Undisclosed | — |
Growth signals
Latest recorded traffic for Altura Medical is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Altura Medical in the San Clemente ecosystem
The Altura Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
SV Health Investors
New Leaf Venture Partners- AVAdvanced Technology Ventures
Other known investors1 additional known investor
University of Minnesota Twin Cities
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Altura Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Altura Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








